ライフサイエンスコーパス: platelet factor

1 ne production, fibrinogen binding sites, and platelet factor 3 activity.

2 proximately twice normal clotting times in a platelet factor 3 availability assay and, in a prothromb

3 disorder associated with development of anti-platelet factor 4 (anti-PF4)/heparin autoantibodies.

4 t survival and decreased plasma thromboxane, platelet factor 4 (CXCL4), and IFN-gamma.

5 tion factor (M-CSF), and chemokines, such as platelet factor 4 (CXCL4).

6 y antibodies against complexes between human platelet factor 4 (hPF4) and heparin.

7 two positively acting sequences in the human platelet factor 4 (hPF4) gene promoter that synergized t

8 ed a panel of HDPs and determined that human platelet factor 4 (hPF4) kills malaria parasites inside

9 Interactions between heparin, human platelet factor 4 (hPF4), antibodies to the hPF4/heparin

10 antimicrobial peptides from human platelets: platelet factor 4 (PF-4), RANTES, connective tissue acti

11 for megakaryocyte specific genes, c-mpl and platelet factor 4 (PF-4).

12 APC) improves survival in severe sepsis, and platelet factor 4 (PF4) accelerates APC generation in a

13 that monocytes complexed with surface-bound platelet factor 4 (PF4) activated by HIT antibodies cont

14 irected to large multimolecular complexes of platelet factor 4 (PF4) and heparin (H).

15 mediated by antibodies to complexes between platelet factor 4 (PF4) and heparin or cellular glycosam

16 antibodies that recognize complexes between platelet factor 4 (PF4) and heparin or glycosaminoglycan

17 therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin.

18 rcoagulable disorder caused by antibodies to platelet factor 4 (PF4) and heparin.

19 oss-linking of Fc gamma RIIA by anti-heparin/platelet factor 4 (PF4) antibodies is central to the pat

20 Additionally, platelet factor 4 (PF4) binds to bacteria and reduces th

21 arin therapy that is caused by antibodies to platelet factor 4 (PF4) complexed with heparin.

22 Although antibodies to heparin-platelet factor 4 (PF4) complexes are found in essential

23 uires detection of antibodies to the heparin/platelet factor 4 (PF4) complexes via enzyme-linked immu

24 The positively charged chemokine platelet factor 4 (PF4) forms immunogenic complexes with

25 Platelet factor 4 (PF4) is a negative regulator of megak

26 Platelet factor 4 (PF4) is a negative regulator of megak

27 Here we discovered that chemokine platelet factor 4 (PF4) is a negative regulator of Th17

28 Platelet factor 4 (PF4) is an abundant platelet alpha-gr

29 Platelet factor 4 (PF4) is an abundant platelet alpha-gr

30 Platelet factor 4 (PF4) is produced by platelets with ro

31 The platelet-specific chemokine platelet factor 4 (PF4) is released in large amounts at

32 e estrogen receptor under the control of the platelet factor 4 (PF4) megakaryocyte-specific promoter.

33 Platelet factor 4 (PF4) serves as a lineage-specific mar

34 e ultralarge complexes (ULCs) of heparin and platelet factor 4 (PF4) tetramers.

35 xes between unfractionated heparin (UFH) and platelet factor 4 (PF4) that form over a narrow molar ra

36 tight electrostatic binding of the chemokine platelet factor 4 (PF4) to polyanions induces heparin-in

37 The chemokine platelet factor 4 (PF4) undergoes conformational changes

38 fic for complexes formed between heparin and platelet factor 4 (PF4), a basic protein found normally

39 Therefore, we investigated the effect of platelet factor 4 (PF4), a cationic protein released in

40 Platelet factor 4 (PF4), a platelet alpha-granule protei

41 Platelet factor 4 (PF4), a platelet-derived CXC chemokin

42 Platelet factor 4 (PF4), a platelet-specific chemokine r

43 Platelet factor 4 (PF4), an abundant platelet alpha-gran

44 we used the megakaryocyte-specific promoters platelet factor 4 (PF4), and glycoprotein IIb (GPIIb) as

45 Immune complexes consisting of heparin, platelet factor 4 (PF4), and PF4/heparin-reactive antibo

46 sorder caused by immune complexes containing platelet factor 4 (PF4), antibodies to PF4 and heparin o

47 exes of platelet activation: platelet count, platelet factor 4 (PF4), beta-thromboglobulin (beta-TG),

48 genes tested, including GPIbalpha, GPIbbeta, platelet factor 4 (PF4), c-mpl, and p45 NF-E2.

49 Immune complexes consisting of platelet factor 4 (PF4), heparin, and PF4/heparin-reacti

50 by four essential components--heparin (Hep), platelet factor 4 (PF4), IgG antibodies against the Hep-

51 neutrophils and have a structure similar to platelet factor 4 (PF4), in which the first two cysteine

52 ific for complexes consisting of heparin and platelet factor 4 (PF4).

53 tiation through the actions of the chemokine platelet factor 4 (PF4).

54 activation, which is further facilitated by platelet factor 4 (PF4).

55 , it forms complexes with positively charged platelet factor 4 (PF4).

56 dies recognize complexes between heparin and platelet factor 4 (PF4).

57 ients with HIT develop autoantibodies to the platelet factor 4 (PF4)/heparin complex, which is termed

58 Antibodies specific for platelet factor 4 (PF4)/heparin complexes are the hallma

59 othrombotic disorder caused by antibodies to platelet factor 4 (PF4)/heparin complexes.

60 h patients tested strongly positive for anti-platelet factor 4 (PF4)/heparin immunoglobulin (Ig)G in

61 This study demonstrates that a human platelet factor 4 (PF4)/heparin-specific murine monoclon

62 g of the HIT-like monoclonal antibody KKO to platelet factor 4 (PF4)/heparin.

63 ility that immune complexes formed following platelet factor 4 (PF4/CXCL4) binding to anti-PF4 antibo

64 onstrate that the platelet-derived chemokine platelet factor 4 (PF4/CXCL4) stimulates VSMC injury res

65 and effectiveness of intravenous recombinant platelet factor 4 (rPF4) as an alternative to protamine

66 cretable form of the antiangiogenic protein, platelet factor 4 (sPF4).

67 s overexpression in transgenic mice (via the platelet factor 4 [PF4] promoter) on megakaryocyte devel

68 ting (IL-3) and growth-inhibitory (MIP-1 and platelet factor 4 [PF4]) cytokines, and extracellular ma

69 ration (glycoprotein [GP] Ibalpha, GPIX, and platelet factor 4 [PF4]), whereas GABPalpha-deficient me

70 iomarkers (fractalkine, platelet P-selectin, platelet factor 4 [PF4], and tumor necrosis factor-alpha

71 nfirmed HIT (4Ts score >/=4 points; positive platelet factor 4 [PF4]/heparin immunoassay, positive se

72 rollary of these concepts is that disrupting platelet factor 4 and beta(2)GPI conformation (or ultral

73 and analyzed for sCD40L, interleukin-6, and platelet factor 4 and beta-thromboglobulin (markers of p

74 In contrast, platelet factor 4 and beta-thromboglobulin do not appear

75 HTTLPR l/l genotype had significantly higher platelet factor 4 and beta-thromboglobulin levels.

76 re more cognitively impaired, and had higher platelet factor 4 and beta-thromboglobulin levels; cardi

77 gin as other markers of platelet activation, platelet factor 4 and beta-thromboglobulin, were not inc

78 of CPB and was similar to that observed for platelet factor 4 and beta-thromboglobulin.

79 th antibodies to complexes that form between platelet factor 4 and glycosaminoglycan (GAG) side chain

80 tibodies against multimolecular complexes of platelet factor 4 and heparin.

81 Platelet-transported inflammatory mediators platelet factor 4 and serotonin accumulated in the graft

82 ibodies over 1 week sustained high levels of platelet factor 4 and serotonin.

83 ts demonstrated that P-selectin, fibrinogen, platelet factor 4 and vascular endothelial growth factor

84 thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.

85 We now show that platelet factor 4 binds to monocytes and forms antigenic

86 n has improved in recent years, with heparin-platelet factor 4 complex as the culprit antigen in most

87 shown that antibodies reactive with heparin-platelet factor 4 complexes lead to FcgammaRIIA-mediated

88 se assay (SRA) and for antibodies to heparin/platelet factor 4 complexes with an ELISA.

89 7082, or TPCA-1) or by genetic manipulation (platelet factor 4 Cre:IKK-beta(flox/flox)), blocked SNAP

90 Platelet factor 4 did not correlate.

91 While the biological basis of platelet factor 4 expression has been pursued by others,

92 lasmic maturation (ie, glycoprotein GPIb and platelet factor 4 expression) and reduced the ability of

93 transcription-induced release of sCD40L and platelet factor 4 in C57BL/6 mice.

94 Roles of IGFBP-1 and platelet factor 4 in HC.HA antiangiogenic action warrant

95 in the absence of clinical disease, such as platelet factor 4 in heparin-induced thrombocytopenia an

96 by determination of beta-thromboglobulin and platelet factor 4 in the supernatants, platelets bound t

97 0, monokine induced by gamma interferon, and platelet factor 4 inhibit epidermal growth factor (EGF)-

98 At this point, 50% of the platelet factor 4 is released, suggesting that half (app

99 PLC-gamma2 and platelet factor 4 mRNA levels were normal.

100 (MIP-1beta), MIP-2, and KC (a member of the platelet factor 4 neutrophil chemoattractant family), as

101 kine C-X-C motif ligand 4 (CXCL4, also named platelet factor 4 or PF4) in the bone marrow, and we fou

102 (tTA), under the control of the MK-specific platelet factor 4 promoter (PF4-tTA-VP16).

103 or transgene expression to platelets using a platelet factor 4 promoter.

104 mbocytopenia antibody" attaches to a heparin-platelet factor 4 protein complex.

105 Serotonin, ADP/ATP, and platelet factor 4 release was profoundly affected in the

106 neration, platelet-derived growth factor and platelet factor 4 release, incorporation of thrombin int

107 hemokines, monokine induced by IFN-gamma and platelet factor 4 that also generate cAMP, inhibited EGF

108 GA6, and increased plasma concentrations of platelet factor 4 under basal conditions.

109 n PEDF and TSP-1 but did contain IGFBP-1 and platelet factor 4 while significantly suppressing neovas

110 Platelet factor 4(PF4), an abundant platelet secretory p

111 l expressed and secreted, RANTES) and CXCL4 (platelet factor 4) to the monocyte surface and endotheli

112 CL4L1, is a homologue of CXCL4 chemokine (or platelet factor 4) with potent anti-angiogenic activity

113 kines, PBP (platelet basic protein) and PF4 (platelet factor 4), are within 5.3 kilobases (kb) of eac

114 subjects with severe asthma, whereas plasma platelet factor 4, a second platelet activation marker,

115 correlated with plasma levels of P-selectin, platelet factor 4, and platelet basic protein in the pop

116 ble factors serotonin (5-hydroxytryptamine), platelet factor 4, and platelet-activating factor, which

117 analyzed with ELISA for soluble P-selectin, platelet factor 4, and thrombospondin-1.

118 e Western blotting of factor V, prothrombin, platelet factor 4, antithrombin III, and fibrinogen.

119 Platelet factor 4, beta-thromboglobulin (betaTG), platel

120 The alpha-granule proteins platelet factor 4, beta-thromboglobulin, and platelet-de

121 role for platelets and their products (e.g., platelet factor 4, beta-thromboglobulin, RANTES, thrombo

122 0, monokine induced by interferon gamma, and platelet factor 4, limit fibroblast responsiveness to gr

123 osaccharides also exhibit low binding toward platelet factor 4, raising the possibility of preparing

124 well as platelet-derived molecules including platelet factor 4, serotonin, P-selectin, and CD154 (CD4

125 Platelet factor 4-Cre-mediated deletion of Slp-76 is suf

126 tibodies show several similarities with anti-platelet factor 4-heparin antibodies and are a potential

127 ene for another platelet-specific chemokine, platelet factor 4.

128 llebrand factor (VWF), thrombospondin-1, and platelet factor 4.

129 :Ag) and propeptide (VWFpp), P-selectin, and platelet factor 4.

130 , with more than 80% of them also containing platelet factor 4.

131 t is for GAG, its binding is not competed by platelet factor 4/CXCL4, and it is present on cells that

132 ted with a high incidence of IgG Abs against platelet factor 4/heparin (PF4/H) complexes by day 6 aft

133 a 4Ts score, rapid particle gel immunoassay (platelet factor 4/heparin [PF4/H]-PaGIA), and serotonin-

134 An ELISA for anti-platelet factor 4/heparin antibodies was performed using

135 Antibodies to the platelet factor 4/heparin complex are a novel, independe

136 We postulated that antibodies to platelet factor 4/heparin complex might contribute to re

137 due primarily to IgG antibodies specific to platelet factor 4/heparin complexes (PF4/Hs) that activa

138 PRT/H Abs showed no cross-reactivity to platelet factor 4/heparin complexes, but were cross-reac

139 heparin therapy caused by antibodies against platelet factor 4/heparin complexes.

140 P483H contains the heparin-binding region of platelet factor-4 (PF-4) and a lysine-rich sequence for

141 evidence that changes in platelet-associated platelet factor-4 (PF-4) detect malignant growth across

142 rostate specific membrane antigen (PSMA) and platelet factor-4 (PF-4) in serum were captured on the a

143 , prostate specific membrane antigen (PSMA), platelet factor-4 (PF-4), and interleukin-6 (IL-6) simul

144 , prostate specific membrane antigen (PSMA), platelet factor-4 (PF-4), and interlukin-6 (IL-6).

145 g to provide direct evidence that tetrameric platelet factor-4 (PF4) and dimeric interleukin-8 (IL8),

146 -10, macrophage-derived chemokine [MDC], and platelet factor-4 [PF-4]) to be expressed by CD34(+) cel

147 binding proteins, such as protamine sulfate, platelet factor-4, and beta-thromboglobulin.

148 , including neutrophil-activating protein-2, platelet factor-4, RANTES, and macrophage chemotactic pr

149 tment with rhMIP-1 beta or rhRANTES, but not platelet factor-4, resulted in improved thymic homing of

150 otein convertase subtilisin/kexin type 9 and platelet factor-4, whereas they had a minimal inhibitory

151 wth-related protein-alpha (Gro-alpha) and to platelet factor-4-M2 (PF4-M2), an N-terminal chimera of

152 Whether platelet factor H is acquired by passive adsorption from

153 secretion of [3H]-5HT (dense core granules), platelet factor IV (alpha granules), or hexosaminidase (

154 trauma, and acquired abnormal coagulation or platelet factors (p < .05).

155 crophage inflammatory protein (MIP)-1 alpha, platelet factor (PF) 4, interferon inducible protein (IP

156 kDa proteins were subsequently identified as platelet factor (PF)4 and connective tissue activating p

157 Platelet factors that were associated with improved plat

158 Measurement of platelet factor V (FV) levels in 7 F5F8D patients (4 wit

159 diathesis appears to reflect the absence of platelet factor V activity.

160 These include platelet factor V and, surprisingly, plasma tissue facto

161 include mild thrombocytopenia and defective platelet factor V.

162 sts may in addition be the result of reduced platelet factor Va expression and modulation of the plat

163 Plasma and platelet factor Va represent different substrates for ac

164 These animals had platelet factor VIII levels equivalent to 3% to 9% plasm

165 y led to platelet aggregation and release of platelet factors which would trigger the proliferation o

166 r collagen at various concentrations exposed platelet factor XI and PAC1 antibody binding in parallel

167 ver, the site of synthesis and the nature of platelet factor XI are not known.

168 atelets expressed approximately 40% of total platelet factor XI but no PAC1 binding sites.

169 secretion, because ADP and collagen exposed platelet factor XI but no S12 binding sites.

170 Thus, platelet factor XI is an alternative splicing product of

171 Platelet factor XI is an alternatively spliced product o

172 Platelet factor XI is associated with the platelet plasm

173 Thus, functionally active platelet factor XI is differentially expressed on platel

174 Enhanced membrane exposure of platelet factor XI is independent of alpha-granule secre

175 he outer surface of growing thrombi, such as platelet factor XI or blood-borne TF, appears essential

176 utive and activation-dependent expression of platelet factor XI.

177 B subunit of factor XIII since placental or platelet factor XIII (A2), which does not contain B subu